Biotech Companies Express Concern With Proposed Changes to the Medicaid Drug Rebate Program (MDRP)
April 11, 2024
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry and create extensive barriers to patient access to existing innovative therapies and to developing new cures for Medicaid enrollees.1 As a result, it will deny some of the nation's most vulnerable patients access to the state-of-the-art medical care they deserve, both now and in the future.
Download Full Comments Below
Biotech Companies Express Concern With Proposed changes to the Medicaid Drug Rebate Program
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry and create extensive barriers to patient access to existing innovative therapies and to developing new cures for Medicaid enrollees.1 As a result, it will deny some of the nation's most vulnerable patients access to the state-of-the-art medical care they deserve, both now and in the future.